Design, synthesis, and structure-activity relationships of aminopyridine N-oxides, a novel scaffold for the potent and selective inhibition of p38 mitogen activated protein kinase

Journal of Medicinal Chemistry

Volumn 52, Issue 17, 2009, Pages 5531-5545

  Lumeras, Wenceslao ^a   Caturla, Francisco ^a   Vidal, Laura ^a   Esteve, Cristina ^a   Balagué, Cristina ^a   Orellana, Adelina ^a   Domínguez, María ^a   Roca, Ramón ^a   Huerta, Josep M ^a   Godessart, Núria ^a   Vidal, Bernat ^a  

^a Almirall SA ^*  (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2,6 DICHLOROPHENYL) 2 (2,4 DIFLUOROPHENYLTHIO)PYRIMIDO[1,6 B]PYRIDAZIN 6 ONE; [3 AMINO 2 (2 METHYLPHENYL) 1 OXIDOPYRIDIN 4 YL](2,4 DIFLUOROPHENYL)METHANONE; [3 AMINO 2 (4 HYDROXY 2 METHYLPHENYL) 1 OXIDOPYRIDIN 4 YL](2,4 DIFLUOROPHENYL)METHANONE; AMINOPYRIDINE DERIVATIVE; AMINOPYRIDINE N OXIDE DERIVATIVE; ANTIINFLAMMATORY AGENT; DORAMAPIMOD; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE 14; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; N OXIDE OXYGEN; OXYGEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADJUVANT ARTHRITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; CHRONIC INFLAMMATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VIVO STUDY; INFLAMMATION; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

AMINOPYRIDINES; ANIMALS; ARTHRITIS, EXPERIMENTAL; CATALYTIC DOMAIN; CELL LINE; DRUG DESIGN; HUMANS; INHIBITORY CONCENTRATION 50; MALE; MODELS, MOLECULAR; OXIDES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE INHIBITORS; RATS; RATS, WISTAR; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 69949090676     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9008604     Document Type: Article

References (48)

1. Han, J.; Lee, J. D.; Bibbs, L.; Ulevitch, R. J. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 1994, 265, 808-811. (Pubitemid 24266145)
2. Raingeaud, J.; Gupta, S.; Rogers, J. S.; Dickens, M.; Han, J.; Ulevitch, R. J.; Davis, R. J. Characterization of the structure and function of a novel MAP kinase kinase (MKK6). J. Biol. Chem. 1996, 271, 2886-2891. (Pubitemid 26055586)
3. Raingeaud, J.; Whitmarsh, A. J.; Barrett, T.; Derijard, B.; Davis, R. J. MKK3- and MKK6-regulated gene expression is mediated by the p38 mitogen-activated protein kinase signal transduction pathway. Mol. Cell. Biol. 1996, 16, 1247.
4. Badger, A. M.; Bradbeer, J. N.; Votta, B.; Lee, J. C.; Adams, J. L.; Griswold, D. E. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J. Pharmacol. Exp. Ther. 1996, 279, 1453-1461.
5. Feldmann, M.; Brennan, F. M.; Maini, R. N. Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 1996, 14, 397-440.
6. Rutgeerts, P.; D'Haens, G.; Targan, S.; Vasiliauskas, E.; Hanauer, S. B.; Present, D. H.; Mayer, L.; van Hogezand, R. A.; Braakman, T.; DeWoody, K. L.; et al. Efficacy and safety of retreatment with anti-tumour necrosis factor antibody (Infliximab) to maintain remission in Chron's disease. Gastroenterology 1999, 117, 761-769.
7. Foster, M. L.; Halley, F.; Souness, J. E. Potential of p38 inhibitors in the treatment of rheumatoid arthritis. Drug News Perspect. 2000, 13, 488-497. (Pubitemid 32063588)
8. Kumar, S.; Boehm, J.; Lee, J. C. p38 MAP kinases: key signaling molecules as therapeutic targets for inflammatory diseases. Nature Rev. Drug Discovery 2003, 2, 717-726. (Pubitemid 37361787)
9. Lee, J. C.; Laydon, J. T.; McDonnell, P. C.; Gallagher, T. F.; Kumar, S.; Green, D.; McNulty, D.; Blumenthal, M. J.; Heyes, J. R.; Landvatter, S. W.; Strickler, J. E.; McLaughlin, M. M.; Siemens, I. R.; Fisher, S. M.; Livi, G. P.; White, J. R.; Adams, J. L.; Young, P. R. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994, 372, 739-746.
10. Vertex USA: Vertex has suspended development of VX-745, a p38 MAP kinase inhibitor, which was in phase II trials in the USA and Europe as potential treatment for rheumatoid arthritis. Vertex Inc., press release (September, 2001).
11. Smith Kline Beecham (now GlaxoSmithKline) has discontinued development of SB 242235, a cytokine suppressor (SmithKline Beecham, April 1999). This product was in phase I clinical studies in the UK (SmithKline Beecham, March 1999) and was being investigated as a potential treatment for rheumatoid arthritis (SmithKline Beecham, April 1999). R&D Focus Report, March 27, 2001.
12. Ferraciola, G. F. VX-745 Vertex Pharmaceutical. Curr. Opin. Anti-Inflammatory Immunomodul. Invest. Drugs 2000, 2, 74-77.
13. Haddad, J. J. VX-745 (Vertex Pharmaceuticals). Curr. Opin. Investig. Drugs 2001, 2, 1070-1076.
14. Zimmiti, C. S.; Schwartz, R.; Torcellini, C. A.; Pargellis, C. A.; Madwed, J. B.; Weldon, S. M. Suppression of p38 activity in vitro and THF alpha production in vivo with BIRB-796 BS, a novel p38 kinase inhibitor. Arthritis Rheum. 2001, 44, S114.
15. Regan, J.; Capolino, A.; Cirillo, P. F.; Gilmore, T.; Graham, A. G.; Hickey, E.; Kroe, R. R.; Madwed, J.; Moriak, M.; Nelson, R.; Pargellis, C. A.; Swinamer, A.; Torcellini, C.; Tsang, M.; Moss, N. Structure-Activity Relationships of the p38R MAP Kinase Inhibitor 1-(5-tert-Butyl-2-p-tolyl-2H- pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)napthalen-1-yl]urea (BIRB-796). J. Med. Chem. 2003, 46, 4676-4686. (Pubitemid 37271617)
16. Devraj, R. V. Discovery and Development of Orally Active p38 Kinase Inhibitors as Anti-TNF Agents. Abstract of Papers, 229th National Meeting of the American Chemical Society, San Diego, CA, March 13-17, 2005; American Chemical Society: Washington, DC, 2005; MEDI-296.
17. Zack, D. J.; Campagnuolo, G.; Middleton, S.; Koch, A.; Zhu, L.; Bolon, B.; Feige, U. Efficacy of AMG 548, a novel p38 kinase inhibitor, in rats with adjuvant-induced or collagen-induced arthritis. 67th Annual Scientific Meeting of the American College of Rheumatology, Orlando, FL, October 23-28, 2003, Abstract 834.
18. Domínguez, C; Liu, L.; Zhang, D.; Tamayo, N.; Powers, D.; Min, W.; Feige, F.; Harris, R.; Wild, S.; Neervannan, S.; Rashid, S.; Harvey, T. p38 MAP kinase: an exciting target for the treatment of inflammatory diseases. Abstract of Papers, 228th National Meeting of the American Chemical Society, Philadelphia, PA; American Chemical Society: Washington, DC, 2004; MEDI-189.
19. Nikas, S. N.; Drossos, A. A. SCIOS-469 (Scios Inc). Curr. Opin. Investig. Drugs 2004, 5, 1205-1212.
20. Perumattan, J. 2-[6-Chloro-5-[4-(4-fluoro-benzyl)-2R,5S-dimethyl- piperazine-1-carbonyl]-1H-indol-3-yl]-2-oxo-acetamides as potent inhibitors of p38 alpha MAP kinase. Drugs Future 2006, 31 (Suppl. A), Abstract O19.
21. Weisman, M.; Furst, D.; Schiff, M.; Kauffman, R.; Merica, E.; Martin-Munley, S. FRI0018 A double-blind, placebo controlled trial of VX-745, an oral p38 MAP kinase inhibitor, in patients with rheumatoid arthritis (RA). Ann. Rheum. Dis. 2002, 61, Suppl. 1.
22. Vertex Pharmaceuticals, Inc. Press Release (September 24, 2001).
23. Wang, Z.; Canagarajah, B. J.; Boehm, J. C.; Kassisa, S.; Cobb, M. H.; Young, P. R.; Abdel-Meguid, S.; Adams, J. L.; Goldsmith, E. J. Structural basis of inhibitor selectivity in MAP kinases. Structure 1998, 6, 1117-1128. (Pubitemid 28434115)
24. Gallagher, T. F.; Seibel, G. L.; Kassis, S.; Laydon, J. T.; Blumenthal, M. J.; Lee, J. C.; Lee, D.; Boehm, J. C.; Fier-Thompson, S. M.; Abt, J. W.; Sorenson, M. E.; Smietana, J. M.; Hall, R. F.; Garigipati, R. S.; Bender, P. E.; Erhard, K. F.; Krog, A. J.; Hoffmann, G. A.; Sheldrake, P. L.; McDonnell, P. C.; Kumar, S.; Young, P. R.; Adams, J. L. Regulation of stress-induced cytokine production by pyridinylimidazoles; inhibition of CSBP kinase. Bioorg. Med. Chem. 1997, 5, 49-64.
25. Liverton, N. J.; Butcher, J. W.; Claiborne, C. F.; Claremon, D. A.; Libby, B. E.; Nguyen, K. T.; Pitzenberger, S. M.; Selnick, H. G.; Smith, G. R.; Tebben, A.; Vacca, J. P.; Varga, S. L.; Agarwal, L.; Dancheck, K.; Forsyth, A. J.; Fletcher, D. S.; Frantz, B.; Hanlon, W. A.; Harper, C. F.; Hofsess, S. J.; Kostura, M.; Lin, J.; Luell, S.; O'Neill, E. A.; Orevillo, C. J.; Pang, M.; Parsons, J.; Rolando, A.; Sahly, Y.; Visco, D. M.; O'Keefe, S. J. Design and Synthesis of Potent, Selective, and Orally Bioavailable Tetrasubstituted Imidazole Inhibitors of p38 Mitogen-Activated Protein Kinase. J. Med. Chem. 1999, 42, 2180-2190.
26. Jackson, P. F.; Bullington, J. L. Pyridinylimidazole based p38 MAP kinase inhibitors. Curr. Top. Med. Chem. 2002, 2, 1011-1020.
27. Collis, A. J.; Foster, M. L.; Halley, F.; Maslen, C.; McLay, I. M.; Page, K. M.; Redford, E. J.; Souness, J. E.; Wilsher, N. E. RPR203494 a Pyrimidine Analogue of the p38 Inhibitor RPR200765A with an Improved in Vitro Potency. Bioorg. Med. Chem. Lett. 2001, 11, 693-696.
28. Revesz, L.; Dipadova, F. E.; Buhl, T.; et al. SAR of 4-Hydroxypiperidine and Hydroxyalkyl Substituted Heterocycles as Novel p38 MAP Kinase Inhibitors. Bioorg. Med. Chem. Lett. 2000, 10, 1261-1264.
29. Fitzgerald, C. E.; Patel, S. B.; Becker, J. W.; Cameron, P. M.; Zaller, D.; Pikounis, V. B.; O'Keefe, S. J.; Scapin, G. Structural Basis for p38α MAP Kinase Quinazolinone and Pyrido-Pyrimidine Inhibitor Specificity. Nat. Struct. Biol. 2003, 10, 764-769.
30. Hunt, J. A.; Kallashi, F.; Ruzek, R. D.; Sinclair, P. J.; Ita, I.; McCormick, S. X.; Pivnichny, J. V.; Hop, C. E. C.; Kumar, S.; m Wang, Z.; O'Keefe, S. J.; O'Neill, E. A.; Porter, G.; Thompson, J. E.; Woods, A.; Zaller, D. M.; Doherty, J. B. p38 Inhibitors: piperidine- and 4-aminopiperidine- substituted naphthyridinones, quinolinones, and dihydroquinazolinones. Bioorg. Med. Chem. Lett. 2003, 13, 467-470.
31. Bao, J.; Hunt, J. A.; Miao, S.; Rupprecht, K. M.; Stelmach, J. E.; Liu, L.; Ruzek, R. D.; Sinclair, P. J.; Pivnichny, J. V.; Hop, C. E. C. A.; Kumar, S.; Zaller, D. M.; Shoop, W. L.; O'Neill, E. A.; O'Keefe, S. J.; Thompson, C. M.; Cubbon, R. M.; Wang, R.; Zhang, W. X.; Thompson, J. E.; Doherty, J. B. p38 MAP kinase inhibitors: Metabolically stabilized piperidine-substituted quinolinones and naphthyridinones. Bioorg. Med. Chem. Lett. 2006, 16, 64-68.
32. Alonso-Alija, C.; Michels, M.; Schirok, H.; Schlemmer, K.-H.; Bell, J.; Fitzgerald, M. F.; Dodd, S.; Gill, A. Monocyclic aroylpyridinones as antiinflammatory agents. Patent WO03076405, September, 2003.
33. Schirok, H.; Alonso-Alija, C.; Benet-Buchholz, J.; Goller, A. H.; Grosser, R.; Michels, M.; Paulsen, H. Efficient Regioselective Synthesis of 6-Amino-5-benzoyl-1-Substituted 2(1H)-Pyridinones. J. Org. Chem. 2005, 70, 9463-9469.
34. Guengoer, T.; Marsais, F.; Queguiner, G. ortho-Functionalization of Aminopyridines. Regioselective Lithiation of 3-Pivaloylaminopyridines. Synthesis 1982, 6, 499-500.
35. (a) Miyaura, N.; Suzuki, A. Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds. Chem. Rev. 1995, 95, 2457-2483 (Review).
36. (b) Stanforth, S. P. Catalytic cross-coupling reactions in biaryl synthesis. Tetrahedron 1998, 54, 263-303 (review).
37. Jin, R.; Bian, Z.; Kang, C.; Guo, H.; Gao, L. Synthesis of 3,3′-Di(2-pyridyl)-1,1′-bi-2-naphthol Derivatives. Synth. Commun. 2005, 35, 1897-1902.
38. Walker, S. D.; Barder, T. E.; Martinelli, J. R.; Buchwald, S. L. A Rationally Designed Universal Catalyst for Suzuki-Miyaura Coupling Processes. Angew. Chem., Int. Ed. 2004, 43, 1871-1876.
39. Negishi, E.-I.; King, A. O.; Okukado, N. Selective carbon-carbon bond formation via transition metal catalysis. 3. A highly selective synthesis of unsymmetrical biaryls and diarylmethanes by the nickel- or palladium-catalyzed reaction of aryl- and benzylzinc derivatives with aryl halides. J. Org. Chem. 1977, 42, 1821-1823.
40. Negishi, E.-I.; Luo, F.-T.; Frisbee, R.; Matsushita, H. A Regiospecific Synthesis of Carbosubstituted Heteroaromatic Derivatives via Pd-Catalyzed Cross Coupling. Heterocycles 1982, 18, 117-122.
41. Wang, Z.; Canagarajah, B. J.; Boehm, J. C.; Kassisa, S.; Cobb, M. H.; Young, P. R.; Abdel-Meguid, S.; Adams, J. L.; Goldsmith, E. J. Structural Basis of Inhibitor Selectivity in MAP Kinases. Structure (London) 1998, 6, 1117-1128. (Pubitemid 28434115)
42. McClure, K. F.; Letavic, M. A.; Kalgutkara, A. S.; Gabel, C. A.; Audoly, L.; Barberiaa, J. T.; Braganzaa, J. F.; Cartera, D.; Cartya, T. J.; Cortinaa, S. R.; Dombroskia, M. A.; Donahuea, K. M.; Elliotta, N. C.; Gibbonsa, C. P.; Jordana, C. K.; Kupermana, A. V.; Labasia, J. F.; LaLibertea, R. E.; McCoya, J. M.; Naimana, B. M.; Nelsona, K. L.; Nguyena, H. T.; Peesea, K. M.; Sweeneya, F. J.; Taylora, T. J.; Trebinoa, C. E.; Abramova, Y. A.; Lairda, E. R.; Volberga, W. A.; Zhoua, J.; Bacha, J.; Lombardo, F. Structure-activity relationships of triazolopyridine oxazole p38 inhibitors: Identification of candidates for clinical development. Bioorg. Med. Chem. Lett. 2006, 16, 4339-4344.
43. Hauser, D. R.; Scior, T.; Domeyer, D. M.; Kammerer, B.; Laufer, S. A. Synthesis, Biological Testing, and Binding Mode Prediction of 6,9-Diarylpurin-8-ones as p38 MAP Kinase Inhibitors. J. Med. Chem. 2007, 9, 2060-2066.
44. Wan, Z.; Boehm, J. C.; Bower, M. J.; Kassis, S.; Lee, J. C.; Zhao, B.; Adams, J. L. N-Phenyl-N-purin-6-yl ureas: The design and synthesis of p38α MAP kinase inhibitors. Bioorg. Med. Chem. Lett. 2003, 13, 1191-1194.
45. Natarajan, S. W.; Wisnoski, D. D.; Singh, S. B.; Stelmach, J. E.; O'Neill, E. A.; Schwartz, C. D.; Thompson, C. M.; Fitzgerald, C. E.; O'Keefe, S. J.; Cornelis, S. K.; Hop, E. C.; Zaller, D. M.; Schmatz, D. M.; Doherty, J. B. p38 MAP kinase inhibitors. Part 1: Design and development of a new class of potent and highly selective inhibitors based on 3,4-dihydropyrido[3,2-d] pyrimidone scaffold. Bioorg. Med. Chem. Lett. 2003, 13, 273-276.
46. Clark, R. D.; Wolohan, P. R. Molecular Design and Bioavailability. Curr. Top. Med. Chem. 2003, 3, 1269-1288.
47. Crystallographic coordinates for the structure of unphosphorylated p38α complexed with 45 have been deposited at the Protein Data Bank (www.rscb.org) with entry accession code 3HRB.
48. See Supporting Information (p S32).